Francis Couturaud
@FCouturaud
Followers
565
Following
6K
Media
47
Statuses
1K
Professor of Pulmonology. MD, PhD Director of the research unit GETBO, UMR 1304, Brest University Hospital, France. Coordinator of the INNOVTE network.
France
Joined September 2019
Systematic search for PE in COPD ? Read this. Thx to all my collègues. Pulmonary Embolism Prevalence Among Patients With COPD With Acutely Worsening Respiratory Symptoms via @JAMA_current part of @JAMANetwork.
jamanetwork.com
This cross-sectional study characterizes the prevalence of pulmonary embolism defined by a uniform diagnostic algorithm in patients in France with COPD hospitalized with acutely worsening respiratory...
6
17
52
RT @TH_Journal: 🫁 Derivation and Validation of a COPD-specific Pulmonary Embolism Diagnostic Strategy ⬇️. 📌 Mai et al. derived a #COPD-spe….
0
9
0
RT @MarcCarrier1: Implementation matters!.A guideline-driven VTE prevention program (Vermont Model) led to ~60% of high-risk cancer patient….
0
8
0
RT @MarcCarrier1: 🩸 Clots tend to come back at the same site as the index VTE!. Among 708 patients with prior VTE, recurrences often occurr….
0
19
0
RT @MaryCushmanMD: Do you dose reduce DOAC for extended prevention of VTE?.💙 Post hoc analysis of RENOVE trial of secondary prevention of V….
0
28
0
RT @MarcCarrier1: 🫁 A COPD-specific diagnostic strategy for PE was retrospectively validated and found to be safe using a 3-item score + D-….
0
12
0
RT @MarcCarrier1: 🩸 New insights from the RENOVE trial (extended duration anticoagulation) at #ISTH2025:. 📉 Reduced-dose DOAC is non-inferi….
0
38
0
Fantastic scientific meeting on 6th June 2026 in Brest by our research group @U1304GETBO, with brillant interventions, international leaders in VTE from @INNOVTE1, in Brest. 70 participants. @capucinsbrest, @FCRIN_network, CHU Brest, @UBO_UnivBrest , @Inserm, CIC1412 inserm.
0
4
11
From Steve Noumegni, one of my brightest PhD student. More about predicting both venous and arterial events after VTE. « Prediction of Recurrent Venous Thromboembolism and Arterial Cardiovascular Events after Discontinuation of Anticoag…
pubmed.ncbi.nlm.nih.gov
Patients who had venous thromboembolism (VTE) are not only at increased risk of recurrent VTE but also of major adverse cardiovascular events (MACEs) than the general population. Therefore, the...
0
2
6
RT @MarcCarrier1: Prof. @isabellemahe1 presents API-CAT at #ACC2025, published in @NEJM Extended anticoagulation with reduced-dose apixaban….
0
82
0
RT @RPTHjournal: Postpartum hemorrhage is a significant risk for many women yet the etiology is not well understood. New study from @demore….
0
11
0
RT @MarcCarrier1: The RENOVE trial found that while low-dose DOACs did not meet non-inferiority for preventing recurrent VTE, it showed a b….
0
1
0
Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial - The Lancet .@INNOVTE1.
thelancet.com
In patients with venous thromboembolism requiring extended anticoagulation, reduction of the direct oral anticoagulant dose did not meet the non-inferiority criteria. However, the low recurrence...
1
12
43
RT @Genevieve_Hery: René Laënnec, médecin breton, né le 17 février (une belle date) 1781 à Quimper et mort de la tuberculose le 13 août 182….
0
22
0
RT @Jmarksloan: RENOVE trial: Full dose vs low dose extended anticoagulation in pts requiring long term AC. Conclusions:.-similar low rat….
0
9
0
RT @MarcCarrier1: @ASH_hematology Late Breaking Abstract:.Should patients receive extended duration anticoagulation with reduced or full do….
0
27
0
RT @MarcCarrier1: Patients with MPN and splanchnic vein thrombosis who are not receiving anticoagulant therapy seem to have a higher risk o….
0
12
0
RT @TregouetBPH: @medrxivpreprint New Genomic Discoveries Pave the Way for Research into Predictive #VT recurrence Factors and Innovative P….
0
3
0
Journées FCRIN @INNOVTE1 à l’HEGP, auditorium Guy Meyer. Une journée riche en projets, finalisés et à venir, cliniques et translationnels, nationaux et internationaux. Quel plaisir de poursuivre cette aventure ensemble!
1
10
34
0
3
0